22 Feb, 2022 Use of cannabis and derived substances in cosmetics – Portuguese approach By Mariana Ricardo Ana Rita Santos The Portuguese National Authority for Medications and Health Products (INFARMED) issued a bulletin on the topic of the usage of cannabis...
18 Feb, 2022 A new chapter in France's CBD legal saga By Marion Abecassis Marion de Galembert In an expected order of 24 January 2022, the interim relief judge of the French Administrative Supreme Court (Conseil d’Etat – “CE”)...
18 Feb, 2022 Clinical Trial Regulations in the EU – how will the UK follow? By Kate Black The European Medicines Agency has confirmed that the new Clinical Trials Regulation is now in effect as of 31 January 2022. Please see...
08 Feb, 2022 An analysis of the effect of drug pricing provisions in the Build Back Better Act on pharmaceutical innovation By Kirsten Axelsen Having previously examined the impact of implementing international reference pricing in the United States, Charles River Associates (a...
02 Feb, 2022 Safety assessment of clinical trials in the EU: how will Member States be involved? By Mariana Ricardo The 31st January marked the day both the EU Clinical Trials Regulation (Regulation (EU) No 534/2014 – “CTR”), and the framework for the...